Neuro

OmniVision Announces Uniquely Small Diameter Cable Modules with Mini-LED Illumination for Single-Use Endoscopes

Tuesday, October 19, 2021 - 2:07pm

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions , today announced the OVMed OCHSA and OCHTA cable modules for single-use endoscope and catheters.

Key Points: 
  • OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions , today announced the OVMed OCHSA and OCHTA cable modules for single-use endoscope and catheters.
  • View the full release here: https://www.businesswire.com/news/home/20211019005614/en/
    OVMed OCHSA and OCHTA Cable Modules (Photo: Business Wire)
    Single-use medical endoscopes will continue to expand at a rapid pace over the coming years.
  • The OCHSA cable module offers 800x800 pixel resolution with high-speed MIPI digital interface for larger outer diameter endoscopes, such as the bronchoscope, thoracoscope, pleuroscope, mediastinoscope, duoendoscope, and aminoscope.
  • OmniVision, OVMed, CameraCubeChip, and the OmniVision logo are trademarks or registered trademarks of OmniVision Technologies, Inc. All other trademarks are the property of their respective owners.

With 16 streams in 10 locations, Creative Destruction Lab (CDL) celebrates its 10th program year

Monday, October 18, 2021 - 12:00pm

Toronto, Ontario, Canada, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Creative Destruction Lab launched in September 2012 with a single cohort of 25 promising science-based startups.

Key Points: 
  • Toronto, Ontario, Canada, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Creative Destruction Lab launched in September 2012 with a single cohort of 25 promising science-based startups.
  • Now entering its tenth year, CDL has supported program participants in creating $15 billion in equity value.
  • Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.
  • It now includes 16 streams: AgTech , Artificial Intelligence , Blockchain , Climate , Commerce , Energy , FinTech , Health , Matter , Neuro , Oceans , Prime (General Technology) , Quantum , Risk , Space , and Supply Chain .

Keynote Speakers Announced for SANS Cyber Solutions Fest

Thursday, October 14, 2021 - 1:20pm

BETHESDA, Md., Oct. 14, 2021 /PRNewswire/ --SANS Institute, the global leader in cyber security training and certifications, announced the keynote speakers for SANS Cyber Solutions Fest, a free two-day virtual event on October 21-22, 2021covering four cybersecurity focus areas: Threat Hunting, SOC/SOAR, MITRE ATT&ACK Framework, and Cloud Security.

Key Points: 
  • BETHESDA, Md., Oct. 14, 2021 /PRNewswire/ --SANS Institute, the global leader in cyber security training and certifications, announced the keynote speakers for SANS Cyber Solutions Fest, a free two-day virtual event on October 21-22, 2021covering four cybersecurity focus areas: Threat Hunting, SOC/SOAR, MITRE ATT&ACK Framework, and Cloud Security.
  • SANS Cyber Solutions Fest will share the latest solutions, tools, and techniques to combat today's cybersecurity threats
    As a result of the recent Executive Order (EO), many U.S. federal agencies are trying to quickly determine next steps in their Zero Trust journey.
  • GIAC, an affiliate of the SANS Institute, validates practitioner skills through more than 35 hands-on, technical certifications in cyber security .
  • The SANS Technology Institute, a regionally accredited independent subsidiary, offersa master's degree, graduate certificates, and an undergraduate certificate in cyber security.

MindMaze and The Royal Buckinghamshire Hospital pioneer first U.K. location-based digital therapeutic solution for brain repair

Thursday, October 14, 2021 - 10:00am

MindPod is the world's first immersive neuro-animation experience a unique form of location-based digital therapeutic that focuses on brain repair through high intensity and high dose complex exploratory movements.

Key Points: 
  • MindPod is the world's first immersive neuro-animation experience a unique form of location-based digital therapeutic that focuses on brain repair through high intensity and high dose complex exploratory movements.
  • Based on technology developed by Johns Hopkins University School of Medicine's Department of Neurology, it is an evidence-based, protocolized, FDA-listed, and CE-Marked neurorestorative solution.
  • "It is a Pixar-level experience which recreates the enriched environments that neuroscience has shown to be beneficial in animal models."
  • MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt.

MindMaze and The Royal Buckinghamshire Hospital pioneer first U.K. location-based digital therapeutic solution for brain repair

Thursday, October 14, 2021 - 10:00am

MindPod is the world's first immersive neuro-animation experience a unique form of location-based digital therapeutic that focuses on brain repair through high intensity and high dose complex exploratory movements.

Key Points: 
  • MindPod is the world's first immersive neuro-animation experience a unique form of location-based digital therapeutic that focuses on brain repair through high intensity and high dose complex exploratory movements.
  • Based on technology developed by Johns Hopkins University School of Medicine's Department of Neurology, it is an evidence-based, protocolized, FDA-listed, and CE-Marked neurorestorative solution.
  • "It is a Pixar-level experience which recreates the enriched environments that neuroscience has shown to be beneficial in animal models."
  • MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt.

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

Wednesday, October 13, 2021 - 3:15pm

The project team will be led by Professor Paul Fitzgerald, of Monash University with 7 scientific collaborators from Monash University, Deakin University and the University of Sydney.

Key Points: 
  • The project team will be led by Professor Paul Fitzgerald, of Monash University with 7 scientific collaborators from Monash University, Deakin University and the University of Sydney.
  • The proposed study is titled Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression and MYND Diagnostics' will play an integral role in the "evaluate" component.
  • MYND Life Sciences, the parent company of MYND Diagnostics INC., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines.
  • The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property.

Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021

Wednesday, October 13, 2021 - 12:30pm

SUNNYVALE, Calif., Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021, after the market close on Wednesday, November 3, 2021.

Key Points: 
  • SUNNYVALE, Calif., Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021, after the market close on Wednesday, November 3, 2021.
  • Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
  • A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the second quarter of fiscal 2022.
  • Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible.

Centinel Spine Wins Second Consecutive Spine Technology Award for its New Angled Endplate Implants for prodisc® L Total Disc Replacement System

Tuesday, October 12, 2021 - 3:00pm

This represents the second consecutive year in winning the Spine Technology Award, also winning in 2020for its two-level indication approval by the FDA for the prodisc L system.

Key Points: 
  • This represents the second consecutive year in winning the Spine Technology Award, also winning in 2020for its two-level indication approval by the FDA for the prodisc L system.
  • Centinel Spine's CEO, Steve Murray, stated, "Centinel Spine is honored to be recognized for this award for a second consecutive year.
  • Centinel Spine continues to lead the total disc replacement market and is the only company with FDA-approved cervical and lumbar total disc replacement devices.
  • The prodisc L remains the only total disc replacement system in the U.S. approved for two-level use in the lumbar spine.

MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13

Monday, October 11, 2021 - 1:35pm

VANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ --MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, today announcedthat MYND Life Sciences CEO, Dr. Lyle Oberg, M.D, will present live at VirtualInvestorConferences.com's Psychedelics Conference on October 13th.

Key Points: 
  • VANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ --MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, today announcedthat MYND Life Sciences CEO, Dr. Lyle Oberg, M.D, will present live at VirtualInvestorConferences.com's Psychedelics Conference on October 13th.
  • Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
  • A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.
  • Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

Investing in Future Scientists, Feinstein Institutes Gets $1.5M NIH Grant to Develop Training Program

Friday, October 1, 2021 - 3:38pm

The grant will support the development of a rigorous training program in translational immunology for two pre-doctoral and one post-doctoral candidates in the Institute of Molecular Medicine at the Feinstein Institutes.

Key Points: 
  • The grant will support the development of a rigorous training program in translational immunology for two pre-doctoral and one post-doctoral candidates in the Institute of Molecular Medicine at the Feinstein Institutes.
  • View the full release here: https://www.businesswire.com/news/home/20211001005517/en/
    Anne Davidson, MBBS, professor in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research.
  • Scientific advancements require training up-and-coming scientists, said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes.
  • The Feinstein Institutes continues to receive significant extramural funding, including a recent $1.3 million NIH grant to study neuro-immune signaling for bioelectronic medicine research and a $2.9 million NIH grant to investigate in-vitro fertilization genetic risk factors .